Avita Medical Q2 2025 Revenue at $18.4M, Projects $76M-$81M 2025 Revenue with Backlog Easing
ByAinvest
Friday, Aug 8, 2025 3:24 pm ET1min read
RCEL--
In the second quarter, commercial revenue increased 21% year-over-year (YoY) to $18.4 million, but was flat sequentially due to a temporary headwind related to a reimbursement issue. The company experienced a significant reduction in demand for its flagship RECELL® System due to delays in Medicare Administrative Contractor (MAC) payments to providers. This issue, which began in January 2025, led to a backlog of unpaid claims, creating uncertainty among providers and dampening demand for the RECELL System [1].
Despite the headwind, Avita Medical's gross profit margin remained strong at 81.2% for the quarter, driven by deeper penetration within customer accounts and new accounts for trauma wounds. The company's gross margin for RECELL products was 84.3% for the quarter, indicating continued profitability for its core product line [1].
Total operating expenses decreased to $26.1 million in Q2 2025 from $28.7 million in Q2 2024, primarily due to reductions in sales and marketing expenses and general and administrative expenses. The company expects to continue reducing operating expenses by approximately $2.5 million per quarter going forward [1].
Avita Medical has taken steps to address the reimbursement issue, with multiple MACs indicating their intent to adjudicate and pay claims under the new codes in July. The company anticipates a recovery in RECELL demand in the second half of 2025 as the claims backlog is resolved [1].
The company's financial results were presented on a webcast and conference call on August 7, 2025, where executives discussed the second-quarter 2025 financial results and provided an outlook for the remainder of the year.
References:
[1] https://www.nasdaq.com/press-release/avita-medical-reports-second-quarter-2025-financial-results-updates-full-year
Avita Medical projects $76M-$81M revenue for 2025, with a rebound expected as the claims backlog eases. In Q2 2025, commercial revenue increased 21% YoY to $18.4M, but was flat sequentially due to a temporary headwind.
Avita Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, reported its second-quarter 2025 financial results, revealing a mixed performance marked by both growth and challenges. The company projects full-year 2025 revenue to range between $76 million and $81 million, down from previous guidance of $100 million to $106 million [1].In the second quarter, commercial revenue increased 21% year-over-year (YoY) to $18.4 million, but was flat sequentially due to a temporary headwind related to a reimbursement issue. The company experienced a significant reduction in demand for its flagship RECELL® System due to delays in Medicare Administrative Contractor (MAC) payments to providers. This issue, which began in January 2025, led to a backlog of unpaid claims, creating uncertainty among providers and dampening demand for the RECELL System [1].
Despite the headwind, Avita Medical's gross profit margin remained strong at 81.2% for the quarter, driven by deeper penetration within customer accounts and new accounts for trauma wounds. The company's gross margin for RECELL products was 84.3% for the quarter, indicating continued profitability for its core product line [1].
Total operating expenses decreased to $26.1 million in Q2 2025 from $28.7 million in Q2 2024, primarily due to reductions in sales and marketing expenses and general and administrative expenses. The company expects to continue reducing operating expenses by approximately $2.5 million per quarter going forward [1].
Avita Medical has taken steps to address the reimbursement issue, with multiple MACs indicating their intent to adjudicate and pay claims under the new codes in July. The company anticipates a recovery in RECELL demand in the second half of 2025 as the claims backlog is resolved [1].
The company's financial results were presented on a webcast and conference call on August 7, 2025, where executives discussed the second-quarter 2025 financial results and provided an outlook for the remainder of the year.
References:
[1] https://www.nasdaq.com/press-release/avita-medical-reports-second-quarter-2025-financial-results-updates-full-year
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet